Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Depreciation & Amortization (CF) (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Depreciation & Amortization (CF) for 10 consecutive years, with $1000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 75.0% to $1000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $1000.0, a 99.13% decrease, with the full-year FY2024 number at $63000.0, down 47.06% from a year prior.
  • Depreciation & Amortization (CF) was $1000.0 for Q2 2025 at Rein Therapeutics, down from $4000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $59000.0 in Q1 2024 to a low of $1000.0 in Q2 2025.
  • A 5-year average of $31533.3 and a median of $40000.0 in 2021 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 97.14% in 2021, then skyrocketed 1950.0% in 2022.
  • Rein Therapeutics' Depreciation & Amortization (CF) stood at $40000.0 in 2021, then grew by 7.5% to $43000.0 in 2022, then rose by 20.93% to $52000.0 in 2023, then plummeted by 92.31% to $4000.0 in 2024, then plummeted by 75.0% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Depreciation & Amortization (CF) are $1000.0 (Q2 2025), $4000.0 (Q2 2024), and $59000.0 (Q1 2024).